Barriers to the use of three-month Paliperidone Palmitate formulation: a study from an Italian real-world setting

References

• Mauri MC, Reggiori A, Paletta S, et al. Paliperidone for the treatment of schizophrenia and schizoaffective disorders - a drug safety evaluation. Expert Opin Drug Saf. 2017 Mar;16(3):365–379. Epub 2017 Feb 9. PMID: 28140680. doi: 10.1080/14740338.2017.1288716
   PubMed Web of Science ®Google Scholar
• Gilday E, Nasrallah HA. Clinical pharmacology of paliperidone palmitate a parenteral long-acting formulation for the treatment of schizophrenia. Rev Recent Clin Trials. 2012 Feb;7(1):2–9. PMID: 22023179. doi: 10.2174/157488712799363307
   PubMedGoogle Scholar
• Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009 Jan 3;373(9657):31–41. Epub 2008 Dec 6. PMID: 19058842. 10.1016/S0140-6736(08)61764-X.
   PubMed Web of Science ®Google Scholar
• Carnovale C, Lucenteforte E, Battini V, et al. Association between the glyco-metabolic adverse effects of antipsychotic drugs and their chemical and pharmacological profile: a network meta-analysis and regression. Psychol Med. 2021 Feb;24(15):1–13. Epub ahead of print. PMID: 33622426. doi: 10.1017/S0033291721000180
   Google Scholar
• Rafaniello C, Pozzi M, Pisano S, et al. Second generation antipsychotics in ‘real-life’ paediatric patients. Adverse drug reactions and clinical outcomes of drug switch. Expert Opin Drug Saf. 2016 Dec;15(sup2):1–8. PMID: 27875914. doi: 10.1080/14740338.2016.1229301
   PubMed Web of Science ®Google Scholar
• Mazhar F, Battini V, Pozzi M, et al. Hyponatremia following antipsychotic treatment: In Silico Pharmacodynamics analysis of Spontaneous reports from the US Food and drug administration Adverse Event Reporting System Database and an Updated systematic review. Int J Neuropsychopharmacol. 2021 Jul 14;24(6):477–489. PMID: 33575781; PMCID: PMC8278799. doi: 10.1093/ijnp/pyab005
   PubMed Web of Science ®Google Scholar
• Karow A, Schnedler D, Naber D. What would the patient choose? Subjective comparison of atypical and typical neuroleptics. Pharmacopsychiatry. 2006 Mar;39(2):47–51. doi: 10.1055/s-2006-931541 PMID: 16555164.
   PubMed Web of Science ®Google Scholar
• Bleakley S, Olofinjana O, Taylor D. Which antipsychotics would mental health professionals take themselves? Psychiatr Bull Cambridge University Press. 2007;31(3):94–96. doi: 10.1192/pb.bp.106.012955
   Google Scholar
• Steinert T. Which neuroleptic would psychiatrists take for themselves or their relatives? Eur Psychiatry. 2003 Feb;18(1):40–41. PMID: 12648897. doi: 10.1016/s0924-9338(02)00004-4
   PubMed Web of Science ®Google Scholar
• McGlashan TH. Is active psychosis neurotoxic? Schizophr Bull. 2006 Oct;32(4):609–613. Epub 2006 Aug 16. PMID: 16914639; PMCID: PMC2632265. doi: 10.1093/schbul/sbl032
   PubMed Web of Science ®Google Scholar
• Emsley R, Parellada E, Bioque M, et al. Real-world data on paliperidone palmitate for the treatment of schizophrenia and other psychotic disorders: a systematic review of randomized and nonrandomized studies. Int Clin Psychopharmacol. 2018 Jan;33(1):15–33. PMID: 28817397. doi: 10.1097/YIC.0000000000000195
   PubMed Web of Science ®Google Scholar
• Nussbaum AM, Stroup TS. Paliperidone palmitate for schizophrenia. Cochrane Database Syst Rev. 2012 Jun 13);6:CD008296. PMID: 22696377 10.1002/14651858.CD008296.pub2
   Google Scholar
• Kane JM, Kishimoto T, Correll CU. Assessing the comparative effectiveness of long-acting injectable vs. oral antipsychotic medications in the prevention of relapse provides a case study in comparative effectiveness research in psychiatry. J Clin Epidemiol. 2013 Aug;66(8 Suppl):S37–41. PMID: 23849151; PMCID: PMC3742035. doi: 10.1016/j.jclinepi.2013.01.012
   PubMed Web of Science ®Google Scholar
• Lamb YN, Keating GM. Paliperidone palmitate intramuscular 3-monthly formulation: a review in schizophrenia. Drugs. 2016 Oct;76(16):1559–1566. PMID: 27699643. doi: 10.1007/s40265-016-0645-5
   PubMed Web of Science ®Google Scholar
• Berwaerts J, Liu Y, Gopal S, et al. Efficacy and safety of the 3-month formulation of paliperidone palmitate vs placebo for relapse prevention of schizophrenia: a randomized clinical trial. JAMA Psychiatry. 2015 Aug;72(8):830–839. PMID: 25820612. doi: 10.1001/jamapsychiatry.2015.0241
   PubMed Web of Science ®Google Scholar
• Savitz AJ, Xu H, Gopal S, et al. Efficacy and safety of paliperidone palmitate 3-month formulation for patients with schizophrenia: a randomized, multicenter, Double-blind, noninferiority study. Int J Neuropsychopharmacol. 2016 Jul 5;19(7):yw018. PMID: 26902950; PMCID: PMC4966278. doi: 10.1093/ijnp/pyw018
   Web of Science ®Google Scholar
• Joshi K, Lafeuille MH, Brown B, et al. Baseline characteristics and treatment patterns of patients with schizophrenia initiated on once-every-three-months paliperidone palmitate in a real-world setting. Curr Med Res Opin. 2017 Oct;33(10):1763–1772. Epub 2017 Aug 4. PMID: 28741387. doi: 10.1080/03007995.2017.1359516
   PubMed Web of Science ®Google Scholar
• Mauri MC, Paletta S, Di Pace C, et al. Paliperidone long-acting plasma level monitoring and a New method of evaluation of clinical stability. Pharmacopsychiatry. 2017 Jul;50(4):145–151. doi: 10.1055/s-0037-1601396 Epub 2017 Mar 9. PMID: 28278537.
   PubMed Web of Science ®Google Scholar
• Herold R. [Long-acting injection - four-times-a-year. Review of the 3-monthly paliperidone-palmitate injection]. Psychiatr Hung. 2017;32(1):96–107. Hungarian PMID: 28424383.
   PubMedGoogle Scholar
• Bioque M, Bernardo M. The current data on the 3-month paliperidone palmitate formulation for the treatment of schizophrenia. Expert Opin Pharmacother. 2018 Oct;19(14):1623–1629. Epub 2018 Sep 24. PMID: 30244607. doi: 10.1080/14656566.2018.1515915
   PubMed Web of Science ®Google Scholar
• Mathews M, Gopal S, Nuamah I, et al. Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia. Neuropsychiatr Dis Treat. 2019 May 21;15:1365–1379. PMID: 31190840; PMCID: PMC6535080. doi: 10.2147/NDT.S197225
   PubMed Web of Science ®Google Scholar
• Lai JK, Margolese HC. A qualitative study of patient experience when switching from paliperidone palmitate once monthly (PP1M) to paliperidone palmitate three monthly (PP3M) long-acting injectable antipsychotic. Schizophr Res. 2019 Feb;204:443–444. Epub 2018 Sep 18. PMID: 30241989. doi: 10.1016/j.schres.2018.09.012
   PubMed Web of Science ®Google Scholar
• Najarian D, Sanga P, Wang S, et al. Noninferiority study comparing paliperidone palmitate 6-month versus the 3-month long-acting injectable in patients with schizophrenia. Int J Neuropsychopharmacol. 2022 Mar 17;25(3):238–251. PMID: 34791283; PMCID: PMC8929757 10.1093/ijnp/pyab071
   PubMed Web of Science ®Google Scholar
• Pacchiarotti I, Tiihonen J, Kotzalidis GD, et al. Long-acting injectable antipsychotics (LAIs) for maintenance treatment of bipolar and schizoaffective disorders: a systematic review. Eur Neuropsychopharmacol. 2019 Apr;29(4):457–470. Epub 2019 Feb 12. PMID: 30770235. doi: 10.1016/j.euroneuro.2019.02.003
   PubMed Web of Science ®Google Scholar
• Özgüven H D, Kir Y. Long acting injectable antipsychotics in the treatment of schizophrenia and Bipolar Disorder. Noro Psikiyatr Ars. 2021 Sep 20;58(Suppl 1):S47–S52. PMID: 34658635; PMCID: PMC8498817 10.29399/npa.27480
   PubMedGoogle Scholar
• Kim SW, Lee YH, Jang JE, et al. Comparison of attitudes toward long-acting injectable antipsychotics among psychiatrists and patients. Int Clin Psychopharmacol. 2013 Mar;28(2):80–86. PMID: 23325306. doi: 10.1097/YIC.0b013e32835d30ae
   PubMed Web of Science ®Google Scholar
• Jaeger M, Rossler W. Attitudes towards long-acting depot antipsychotics: a survey of patients, relatives and psychiatrists. Psychiatry Res. 2010 Jan 30;175(1–2):58–62. Epub 2009 Dec 11. PMID: 20004980 10.1016/j.psychres.2008.11.003
   PubMed Web of Science ®Google Scholar
• Hamann J, Kissling W, Heres S. Checking the plausibility of psychiatrists׳ arguments for not prescribing depot medication. Eur Neuropsychopharmacol. 2014 Sep;24(9):1506–1510. Epub 2014 Jul 4. PMID: 25037772. doi: 10.1016/j.euroneuro.2014.06.015
   PubMed Web of Science ®Google Scholar
• Bernardo M, Bioque M. Three-month paliperidone palmitate - a new treatment option for schizophrenia. Expert Rev Clin Pharmacol. 2016 Jul;9(7):899–904. Epub 2016 Jun 6. PMID: 27206330. doi: 10.1080/17512433.2016.1191945
   PubMed Web of Science ®Google Scholar
• Correll CU, Citrome L, Haddad PM, et al. The use of long-acting injectable antipsychotics in schizophrenia: evaluating the evidence. J Clin Psychiatry. 2016;77(suppl 3):1–24. PMID: 27732772. doi: 10.4088/JCP.15032su1
   PubMed Web of Science ®Google Scholar
• World Medical Association. World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. Bull World Health Organ. 2001;79(4):373–374. Epub 2003 Jul 2. PMID: 11357217; PMCID: PMC2566407.
   PubMed Web of Science ®Google Scholar
• Taylor D, Olofinjana O. Long-acting paliperidone palmitate - interim results of an observational study of its effect on hospitalization. Int Clin Psychopharmacol. 2014 Jul;29(4):229–234. PMID: 24419004; PMCID: PMC4047303. doi: 10.1097/YIC.0000000000000028
   PubMed Web of Science ®Google Scholar
• Nikolić N, Page N, Akram A, et al. The impact of paliperidone palmitate long-acting injection on hospital admissions in a mental health setting. Int Clin Psychopharmacol. 2017 Mar;32(2):95–102. PMID: 27898432. doi: 10.1097/YIC.0000000000000155
   PubMed Web of Science ®Google Scholar
• R Core Team. R: a language and environment for statistical computing. Vienna Austria: R Foundation for Statistical Computing; 2021. URL https://www.R-project.org/
   Google Scholar
• Garcia-Portilla MP, Llorca PM, Maina G, et al. Symptomatic and functional outcomes after treatment with paliperidone palmitate 3-month formulation for 52 weeks in patients with clinically stable schizophrenia. Ther Adv Psychopharmacol. 2020 May 25;10:2045125320926347. PMID: 32518617; PMCID: PMC7252374. doi: 10.1177/2045125320926347
   Web of Science ®Google Scholar
• DerSarkissian M, Lefebvre P, Joshi K, et al. Health care resource utilization and costs associated with transitioning to 3-month paliperidone palmitate among US veterans. Clin Ther. 2018 Sep;40(9):1496–1508. Epub 2018 Aug 23. PMID: 30145029. doi: 10.1016/j.clinthera.2018.07.011
   PubMed Web of Science ®Google Scholar
• Vincent PD, Demers MF, Doyon-Kemp V, et al. One year mirror-image study using paliperidone palmitate for relapse prevention of schizophrenia in four university hospitals in Canada. Schizophr Res. 2017 Jul;185:96–100. doi: 10.1016/j.schres.2017.01.013 Epub 2017 Jan 22. PMID: 28119036.
   PubMed Web of Science ®Google Scholar
• Lee D, Lee BC, Choi SH, et al. Effects of paliperidone palmitate on healthcare utilization and costs for patients with schizophrenia: a Claim-based mirror-image study in South Korea. Clin Psychopharmacol Neurosci. 2020 May 31;18(2):303–310. PMID: 32329310; PMCID: PMC7242100. doi: 10.9758/cpn.2020.18.2.303
   PubMed Web of Science ®Google Scholar
• Pappa S, Mason K. Partial compliance with long-acting paliperidone palmitate and impact on hospitalization: a 6-year mirror-image study. Ther Adv Psychopharmacol. 2020 May 22;10:2045125320924789. PMID: 32547731; PMCID: PMC7249591. 10.1177/2045125320924789
   Web of Science ®Google Scholar
• Devrimci-Ozguven H, Atmaca M, Baran Z, et al. Efficacy and safety of paliperidone palmitate treatment in patients with schizophrenia: a real-world multicenter, retrospective, mirror-image study. J Clin Psychopharmacol. 2019 Nov;39(6):604–610. PMID: 31688391. doi: 10.1097/JCP.0000000000001133
   PubMed Web of Science ®Google Scholar
• Oh SY, Jon DI, Hong HJ, et al. The impact of paliperidone palmitate on hospitalization in patients with schizophrenia: a retrospective mirror-image study. Clin Psychopharmacol Neurosci. 2019 Nov 20;17(4):531–536. PMID: 31671491; PMCID: PMC6852671. doi: 10.9758/cpn.2019.17.4.531.
   PubMed Web of Science ®Google Scholar
• Caliskan AM, Calisir S, Caliskan S, et al. Impact of initiating long-acting injectable paliperidone palmitate on relapse and hospitalization in patients with bipolar I disorder: a mirror image retrospective study. Asian J Psychiatr. 2020 Dec;54:102457. doi: 10.1016/j.ajp.2020.102457 Epub 2020 Oct 24. PMID: 33271736.
   PubMed Web of Science ®Google Scholar
• Abdel-Baki A, Medrano S, Maranda C, et al. Impact of early use of long-acting injectable antipsychotics on psychotic relapses and hospitalizations in first-episode psychosis. Int Clin Psychopharmacol. 2020 Jul;35(4):221–228. PMID: 32282448. doi: 10.1097/YIC.0000000000000310
   PubMed Web of Science ®Google Scholar
• Heres S, Lambert M, Vauth R. Treatment of early episode in patients with schizophrenia: the role of long acting antipsychotics. Eur Psychiatry. 2014 Nov;29 Suppl 2:1409–1413. Epub 2014 Nov 22. PMID: 25455704. doi: 10.1016/S0924-9338(14)70001-X
   PubMedGoogle Scholar
• Degli Esposti L, Sangiorgi D, Mencacci C, et al. Pharmaco-utilisation and related costs of drugs used to treat schizophrenia and bipolar disorder in Italy: the IBIS study. BMC Psychiatry. 2014 Oct 14;14:282. PMID: 25312446; PMCID: PMC4203906. 10.1186/s12888-014-0282-z
   PubMed Web of Science ®Google Scholar
• ISTAT. ISTAT-Rapporto annuale 2017 2021. https://www.istat.it/it/archivio/199318 (accessed Dec 8, 2021).
   Google Scholar
• Rapporto Nazionale OsMed 2020 sull’uso dei farmaci in Italia n.d. https://www.aifa.gov.it/-/rapporto-nazionale-osmed-2020-sull-uso-dei-farmaci-in-italia (accessed Dec 8, 2021).
   Google Scholar
• Potkin S, Bera R, Zubek D, et al. Patient and prescriber perspectives on long-acting injectable (LAI) antipsychotics and analysis of in-office discussion regarding LAI treatment for schizophrenia. BMC Psychiatry. 2013 Oct 16;13:261. PMID: 24131801; PMCID: PMC3819472. 10.1186/1471-244X-13-261
   PubMed Web of Science ®Google Scholar
• Weiden PJ, Roma RS, Velligan DI, et al. The challenge of offering long-acting antipsychotic therapies: a preliminary discourse analysis of psychiatrist recommendations for injectable therapy to patients with schizophrenia. J Clin Psychiatry. 2015 Jun;76(6):684–690. PMID: 25939027. doi: 10.4088/JCP.13m08946
   PubMed Web of Science ®Google Scholar
• Kishimoto T, Nitta M, Borenstein M, et al. Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies. J Clin Psychiatry. 2013 Oct;74(10):957–965. PMID: 24229745. doi: 10.4088/JCP.13r08440
   PubMed Web of Science ®Google Scholar